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ABSTRACT OF THESIS 
 
 
 
 
THE INFLUENCE OF ANTIDIABETIC MEDICATIONS ON THE DEVELOPMENT 
AND PROGRESSION OF PROSTATE CANCER 
 
 
The development of prostate tumors has been linked to co-morbid 
diabetes mellitus (DM) in several studies, potentially through the stimulation of 
insulin-like growth factor receptor (IGFR). This study evaluates the effect of anti-
diabetic medication use on the development of high grade tumors and time to 
tumor progression compared to non-diabetics. This retrospective, nested case 
control study identified patients with prostate cancer (PCa) from the Kentucky 
Medicaid Database. Cases were diagnosed with PCa and DM and using at least 
one of the following antidiabetic medications; sulfonylureas, insulin, metformin or 
TZDs. Cases were further stratified on their insulin exposure resulting from 
therapy. Controls were those with PCa without  DM or  any anti-diabetic 
medications. No statistically significant effects on insulin exposure was found on 
tumor grade and time to progression. Trends identified that use of metformin or 
TZDs potentially decreased the odds of high-grade tumors and decreased the 
risk of progression, while sulfonylureas and high-dose insulin may increase the 
odds of high-grade tumors and increase the risk of progression compared to non-
diabetics. Future studies should be conducted to further evaluate the effects of 
anti-diabetic medications on tumor grade and time to prostate cancer 
progression.  
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SECTION ONE: BACKGROUND 
 
Prostate cancer (PCa) is the most common cancer of men in the United States, 
affecting nearly 2.4 million men in 2008.1 Currently 11.8% of the adult male 
population (13 million men) are estimated to have a diagnosis of diabetes, 90-
95% of which is considered to be type II (T2DM).2 While the most prominent long 
term effects of diabetes are cardiovascular complications, recent studies have 
demonstrated a relationship between diabetes, diabetes treatments and cancer 
risk.3-9  
 
In investigating the association, the presence of diabetes was found to 
independently correlate with lower prostate specific antigen (PSA) levels.10 
Looking at how this may translate into overall cancer risk, the Physician’s Health 
Study found that diabetics were 36% less likely to develop prostate cancer than 
non-diabetics, a finding that has been supported in other trials.3,6,11,12 
Interestingly, the duration of diabetes diagnosis also appears to affect this 
relationship, with those with long-standing T2DM having a lower risk than newly 
diagnosed patients, namely due to the progressive nature of insulin 
resistance.13,14 Furthermore, in those that do develop cancer, diabetes appears 
to have an effect on tumor grade, with some studies reporting a direct 
relationship in prostate tumors while others demonstrate inverse correlation.6,15-19 
Although numerous hypothesis have been proposed to explain this causal 
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relationship, one prominent rationale focuses on the role of insulin exposure and 
the insulin-like growth factor receptor (IGF-1R) in tumorgenesis.4,5,7  
 
Insulin-like growth factor 
 
IGF-1R is a dimeric type 2 tyrosine kinase receptor expressed on both normal 
tissue as well as numerous cancer cell lines. It is structurally similar to the insulin 
receptor (IR) and may form hetero-dimer hybrids with IR on cells that co-express 
both receptors.20,21 Stimulation of IGF-1R is associated with numerous 
downstream actions including the activation of mitogenic and anti-apoptotic 
mechanisms such as the P13K/AKT and RAS/RAF/MAPK signaling pathways, 
stimulation of which have a known effect on oncogenesis. These activations are 
essential in cell growth, proliferation and survival; mutations in these pathways 
have been shown to lead to aberrant uncontrolled cell growth.22 The effects of 
IGF-1R and its primary ligand, insulin-like growth factor (IGF-1) on the 
development of cancer have been evaluated in numerous cell and animal 
models.21-24   
 
Specifically IGF-1R, insulin receptors and hetero-dimers have been shown to be 
over-expressed in both normal and malignant prostate tissue. Studies have 
demonstrated a trend of increasing levels of expression being associated with 
increased levels of prostate specific antigen (PSA) and higher Gleason score 
values, both of which indicate increased aggressiveness and poorer prognosis.25-
3 
27 Recent evaluation of IGF-1R antagonism in prostate tumor cells has 
demonstrated a decrease in both androgen dependant and androgen 
independent cell growth, furthering the hypothesis that IGF-1R activation may 
accelerate tumor progression.23  
 
While IGF-1 is the most common cause of IGF-1R stimulation, insulin has also 
been demonstrated to bind and activate the IGF-1 receptor, leading to increased 
cellular proliferation and anti-apoptosis.21,22,28 Increased measured insulin levels 
have been linked to not only a higher incidence of prostate cancer, but also 
potentially increased Gleason scores and cancer-related mortality.7,16,29 Lehrer et 
al. found that men presenting with higher grade tumors had higher measured 
circulating insulin, although the diabetic status of these patients was not noted.16  
Further in a study by  Venkateswaran et al. mice with a diet-induced measured 
hyperinsulinemic state had an increase in prostate tumor size over those with 
normal levels.30 These studies support the hypothesis that the acute elevation in 
insulin seen in initial diabetes development impacts tumor growth, while the 
overall long term decrease in circulating insulin affects tumor development.   
 
Serum insulin levels and PCa 
 
Antidiabetic pharmacotherapy can influence the levels of exogenous and 
endogenous insulin, potentially impacting tumor development.31 Weinstein et al. 
found that insulin analogues (glargine, detemir) increased mitogenic growth 
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similar to direct application of IGF-1 on tumor cells. In these cells, the rate of 
proliferation increased by 14-16% in glargine and detemir treated cells, while the 
percentage of apoptotic cells decreased by 5.1-8.3% compared to controls 
(p<0.05).28 This finding was confirmed in an epidemiologic study by Hemkens et 
al. that found a dose-dependent OR 1.09-1.31 times (p<0.0001) greater risk of 
cancer for those using insulin glargine over regular human insulin.32 This 
increase in cellular proliferation, especially prominent with the increased 
exposure of longer acting agents provides further evidence of the relationship of 
insulin and prostate cancer cell growth.  
 
Looking at the use of oral agents, conflicting data exists regarding the role that 
oral anti-diabetic agents play in the development of prostate tumors. Bowker et 
al. linked the use of insulin and insulin-secretagogue agents (i.e. sulfonylureas) 
with an increased risk of cancer-related mortality across all cancer types. 
Patients with any use of sulfonylureas had a 1.3 times higher cancer-related 
mortality than those on metformin, a non-secreting agent, while any use of insulin 
increased the risk by 1.9 times versus non-insulin users.33  Compared to insulin-
stimulating agents, thiazolidinediones (TZDs) appear to have little to no effect on 
the development of any cancer type, although the results are inconsistent.34,35  
 
Specifically evaluating prostate tumors, Murtola et al. reported a lower risk of 
prostate tumor development with all users of oral antidiabetic therapy (metformin, 
sulfonylureas, or other oral agents) compared to non-diabetic non-users, 
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although this did not differentiate between disease effect versus the effect of the 
medications used to managed diabetes. Currie et al. reported a non-statistically 
significant increase in prostate cancer risk for those treated with sulfonylurea 
monotherapy, sulfonylurea + metformin therapy or insulin-based therapies 
compared to those using metformin as a single agent.36 On the contrary, a large 
cohort analysis from the Kaiser Permanente Northern California Diabetes 
Registry, the ever-use of any oral antidiabetic therapy (sulfonylureas, metformin 
and TZDs) was not associated with any change in the development of prostate 
tumors.37 From this information it is clear that the interaction of these agents with 
tumor development and growth is unclear and more investigation is needed to 
guide prudent medication selection in diabetic men at-risk for prostate tumors. 
 
Covariate relationship 
 
In addition to these observed relationships, other factors may also impact the 
complex interactions of prostate cancer and diabetes and should be accounted 
for in future study. Bisphosphonates are often used to prevent and treat bone 
metastases and may reduce the adhesion and invasion of metastasized tumor 
cells, potentially prolonging the time to progression.38 Other concurrent 
medications, such as corticosteroids, are commonly used in the management of 
prostate tumors and may lead to hyperglycemia.39 The increased presence of 
serum glucose stimulates insulin production in non-diabetic patients and may 
necessitate increased medication doses in diabetic patients. Additionally, recent 
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research has suggested that obesity, hypertension, hypercholesterolemia, either 
individually or as metabolic syndrome may also play a role in the development of 
higher-grade cancer (Gleason score ≥ 7) as well as increased progression.8,40 
These findings appear to be independent of concurrent diabetes and are thought 
to potentially be through alterations in sex-hormones.8 Finally, use of androgen 
deprivation therapy (ADT) in the treatment of prostate tumors has also been 
linked to the increased development of diabetes and metabolic syndrome in 
previously undiagnosed patients and may also affect tumor development.41  
 
Aside from concurrent medication use and medical diagnoses, social factors may 
also influence the development and progression of prostate cancer. Numerous 
studies have cited that patients living in more rural areas have reduced access to 
health, leading to poorer outcomes across disease states. Specifically, how far 
patients live from their treating physician has been associated with worsening 
overall glycemic control and may impact the presence of serum insulin.42 In 
regards to prostate cancer outcomes, men in rural areas away from treatment 
centers are less likely to undergo more aggressive radiation therapy as those 
living in more metropolitan areas.43,44 In addition to the decreased access to care 
seen in rural patients, other, non-medical exposures may also impact the 
characteristics of prostate tumors in more agrarian areas. While not commonly 
encountered, several occupational investigations have cited that farmers have an 
increased risk and mortality of prostate tumors.45-47 
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The relationship between insulin, diabetes and prostate cancer is complex with 
multiple modifying factors. An improved characterization of this association on 
the development and progression of prostate tumors could potentially impact 
thousands of patients. Based upon previous epidemiologic, animal and in vitro 
studies we hypothesize that increased insulin exposure induced by endogenous 
insulin or oral insulin secretagogues will increase the initial tumor invasiveness 
as measured by Gleason score and shorten the time to disease progression. 
 
SECTION TWO: METHODS 
 
Study Design 
 
This was a retrospective nested case-control study of the Kentucky Medicaid 
population. The Kentucky Medicaid (KM) database contains billing information on 
the healthcare utilization, including procedures, medication use and diagnoses, 
of low-income patients. Data within the KM database is available through the 
International Disease Classification 9th revision (ICD-9) and Current Procedural 
Terminology (CPT) codes. Data prior to January 1, 2000 was not available and 
after December 31, 2005, outpatient prescription drug coverage of patients >65 
years of age was transitioned to coverage through the national Medicare Part D 
program and was no longer available through the Kentucky Medicaid (KM) 
database.  
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In addition to information from the KM database, the Kentucky Cancer Registry 
(KCR) was also used for data collection and validation. The KCR is a mandatory 
state cancer reporting system that is part of the National Cancer Institute’s 
Surveillance Epidemiology End Results (SEER) program. All state healthcare 
facilities are required by law to report all new cancer diagnoses to the registry. 
Through participation in SEER, cases are validated and additional demographic, 
pathologic, and survival information is collected.48  
 
This study protocol was reviewed and approved through the Institutional Review 
Board (IRB) at the University of Kentucky and the Kentucky Cabinet for Health 
and Family Services (KCHFS). An independent board at the Kentucky Cancer 
Registry also approved the use of this protocol upon recommendation from the 
University of Kentucky and KCHFS. 
 
Study Population  
 
All male patients >18 years age who were found to have a diagnoses of prostate 
cancer between July 1, 2000 and December 31, 2005, as defined below, were 
established for inclusion. Patients were followed from diagnosis until the last date 
of contact or August 31, 2009, whichever came first. Patients must have had 
Medicaid enrollment for >11 months to allow for medication use analysis.  
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Diagnosis of prostate cancer was determined through the identification of the 
ICD-9 diagnosis codes for primary prostate gland cancer (PGC) (ICD9 185.x) 
and primary prostate utricle cancer (PUC) (ICD9 189.3) within the KM database. 
Patients with benign lesions or carcinoma in situ were excluded. Patients must 
have had at least two cancer related visits to a healthcare provider within 1 year. 
Patients with a diagnosis of prostate cancer through the KM database were then 
linked to information from the KCR to validate diagnosis dates and provide 
pathologic and staging data. In the event of a discrepancy for diagnosis date 
between the two databases, the date given by KCR was utilized due to the 
independent validation of this dataset. 
 
Diagnosis of diabetes mellitus was determined using the Healthcare 
Effectiveness Data and Information Set (HEDIS) definition. Patients with two type 
II diabetes (T2DM) related healthcare visits (defined by the presence of ICD 
250.x2 or 250.x0) and a prescription for an antidiabetic medication filled within 1 
year were considered to have diabetes. The presence of type I diabetes was not 
eligible for study inclusion due to the lack of endogenous insulin and inability to 
use oral antidiabetic medications of this patient population. 
 
Insulin exposure groups were determined based on the use of antidiabetic 
medications within the KM database. Medications were determined through the 
use of NDC codes; a complete list of medications used within the study is 
available in Appendix Table 1.. Patients with the use of sulfonylureas, insulin at 
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doses >0.8 units/kg/day (high-dose; utilized an average weight of 85kg 
determined from internal data on the weight of prostate cancer patients in 
Kentucky) or combination therapy for >2/3 the entire study period involving either 
of these agents were considered to have elevated insulin exposure. Patients 
using metformin, TZDs, insulin at doses ≤0.8 units/kg/day, or combination 
therapy for >2/3 of the study period without high-dose insulin or sulfonylureas 
were considered to have physiologic insulin exposure. Those without the use of a 
clear combination medication therapy for >2/3 the study period, one-time 
medication use or poor diabetes medication compliance were considered to have 
indeterminate insulin exposure. Patients without a diagnosis of type I or type II 
diabetes, or the receipt of an antidiabetic medication at any time during the study 
observation were considered control subjects. Since age is a key determinate in 
the progression of aggressive of prostate tumors and a well known confounder, 
cases were age-matched to controls in randomized blocks of 2, allowing for up to 
2 controls present in the analysis for every case. 
 
Patients with an ICD-9 diagnosis of diabetes, but who do not have a prescription 
for diabetes treatment during the study period were excluded. These include 
patients who may be utilizing therapeutic lifestyle changes for glucose control 
and may have less predictable insulin exposure. Patients utilizing therapy with 
repaglinde, nateglindine, α-glucosidase inhibitors were not included due to 
variable insulin exposure. Newer agents such as exenatide, pramlintide or 
sitagliptin were not present in the Medicaid population during the study period.  
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In addition to the diagnosis of prostate cancer and diabetes, information on age, 
presence of diabetes, medication use (including steroid and bisphosphonate 
use), geography, comorbid disease, tumor grade, tumor stage, metastatic sites, 
surgical information, time with diagnosis of diabetes within the study period and 
compliance was collected. Medication use was defined as use prior to diagnosis 
(for primary analysis) or recurrence (for secondary analysis); steroid use was 
limited to those with use for ≥30 days. Geography was determined through the 
use of the United States Department of Agriculture (USDA) Rural-Urban 
continuum codes.49 Based on their primary residence, patients were divided into 
urban, suburban and rural areas based on their proximity to large metro areas. 
Co-morbid disease was primarily measured in the KM database through the use 
of the Charlson score. The Charlson score is a weighted composite score that 
evaluates the presence of 22 conditions (e.g. heart disease, hypertension, 
pulmonary dysfunction, diabetes, AIDS, renal dysfunction, etc.).50 For this 
analysis, the Charlson score calculated prior to the diagnosis of cancer was 
utilized to reduce falsely elevated comorbid disease. Charlson data was not 
available for all patients, so in addition the the presence of a hypertension or 
hypercholesterolemia diagnosis in the Medicaid database with subsequent 
prescription medication treatment was also included as a separate measure of 
comorbid disease Medication Possession Ratio (MPR) was used to evaluate 
medication compliance of diabetes medications and determine study inclusion. 
MPR is calculated as the sum of the days supply medication over a time period 
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divided by the time period of evaluation.51 An MPR of <80% was used to 
determine poor diabetes medication compliance and led to study exclusion. 
 
Determination of endpoints 
Gleason score information is available as part of the KCR database from 
pathology reports at the time of diagnosis. Patients with a Gleason score <7 were 
considered to have low grade, less aggressive disease while those with a 
Gleason score ≥7 were considered to have high grade, more aggressive tumors.  
 
Time to progression was defined as a composite endpoint classified through the 
use of ICD-9 and CPT codes within the KM database. Patients that experienced 
any of the following events ≥ 60 days after the diagnosis of prostate cancer were 
considered to have progressed: 
1. Appearance of elevation of PSA ICD-9 code (790.93) at any point after the 
index date of PSA normalization. 
2. Initiation of chemotherapy determined through CPT codes 96401-96549 or 
the presence of chemotherapy within the KM prescription database (low 
dose oral methotrexate was excluded). 
3. Development of a secondary cancer diagnosis in patients who were not 
diagnosed at a metastatic stage. This was determined through ICD9 
codes and based on reasonable sites of metastatic spread of prostate 
cancer including bone/spine, regional lymph nodes, bladder, kidney, liver, 
lung, colon/rectum and other pelvic/genital structures.52 
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Statistical Analysis 
 
Demographic variables were evaluated using descriptive statistics. Simple 
comparisons of continuous variables between the study groups was conducted 
using ANOVA testing for normally distributed data and Kruskal-Wallis testing for 
non-parametric variables. Categorical variables were evaluated using chi-square 
testing of independence; however, when low cell counts were found, Fisher’s 
exact testing was utilized instead. 
 
The primary endpoint was the presence of low Gleason score at diagnosis. An 
odds ratio of the presence of low Gleason score between cases and controls was 
evaluated through bivariate and multivariate conditional logistic regression to 
control for confounders. Conditional logistic regression allows for comparison 
between matched groups; using this test provided for appropriate analysis 
between the age-matched cases and controls. The conditional multivariate 
regression included known confounders of geography, comorbidity measure and 
steroid use prior to diagnosis regardless of the results of the bivariate model. The 
secondary endpoint was the time to progression as defined above. Kaplan Meier 
survival curves and log-rank testing was used to evaluate the differences in time 
to progression between insulin exposure groups. To account for potential 
confounding covariates, a Cox Proportional Hazard regression model was 
created to evaluate the overall hazard ratios, again accounting for known 
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confounders of geography, comorbidity, stage/metastatic spread, and steroid and 
bisphosphonate use prior to recurrence. Patient with missing data used in the 
regression models were excluded from the regression analysis. Statistical 
analysis was performed using STATA v.10 (StataCorp LP, College Station, TX, 
USA). 
 
SECTION THREE: RESULTS 
 
Out of 1272 patients initially identified, 722 patients were eligible for inclusion. A 
diagram of exclusion is provided in Figure 1. Of these patients, 50 were found to 
have physiologic insulin exposure, 103 had elevated insulin exposure, and 16 
had indeterminate exposure. The remaining 569 patients had no evidence of 
diabetes. From this, 338 were randomly age-matched and selected as controls. 
Those with indeterminate exposure were excluded from the final analysis due to 
low numbers, leading to a total of 491 patients evaluated. Demographic 
information is listed in Table 1. 
 
Within the 491 patients, 236 were found to have evaluable pathologic 
information, including Gleason score, provided by the Kentucky Cancer Registry. 
One-hundred forty-nine (59.36%) were found to have a low Gleason score (<7), 
while 102 (40.64%) were diagnosed with high-grade disease. A breakdown of 
this by insulin exposure group is in Figure 2. Overall diabetic patients, regardless 
of insulin exposure, presented with lower Gleason scores, although this was not 
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statistically significant. Compared to those without diabetes, patients with 
elevated exposure had a 5% lower odds (95% CI: 0.47-1.91; p=0.887) of 
developing high-grade disease, while those with physiologic exposure had a 45% 
lower odds (95% CI: 0.21-1.46; p=0.233). When adjusted for geography, co-
morbidity (measured as Charlson score), and corticosteroid use prior to prostate 
cancer diagnosis, elevated insulin exposure appeared to slightly increase the 
odds of presenting with high-grade disease (OR=1.04 (0.44-2.44); p=0.685), 
while physiologic insulin exposure decreased the odds (OR=0.62 (0.22-1.70); 
p=0.929) compared to controls (Table 2). 
 
Only 299 patients had complete information using the Charlson score as the 
measure of comorbidity; 133 had evaluable Gleason scores. Eliminating the 
Charlson score measure of comborbidity from the model to increase the 
evaluable population to 236, both elevated and physiologic insulin exposure was 
found to slightly lower the odds of being diagnosed with a low Gleason score 
(Appendix Table 2). Hypercholesterolemia and hypertension are the most 
clinically significant comorbid diseases; through the substitution of these 
variables as the measure of comorbidity, the evaluable population in the model 
was retained at 236 patients, while still allowing for adjustment of the effect of 
comorbid disease.  Through this, elevated insulin exposure appeared to have no 
effect on high-grade disease, while physiologic insulin exposures trended to 
lower Gleason scores at diagnosis (elevated insulin OR=1.00 (0.49-2.08); 
p=0.988) (physiologic insulin OR=0.59(0.22-1.60); p=0.304)) compared with 
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those without diabetes. (Appendix Table 3). Additionally, the duration of diabetes 
diagnosis prior to prostate cancer was also evaluated, but was found to have a 
non-significant impact on the development of high-grade prostate cancer 
(Appendix Table 4). 
 
Evaluating the secondary endpoint (Figure 3), 122 patients were found to have 
recurrence. Median time to recurrence was 31.4 (0.03-98.1) months for those 
with physiologic exposure compared to 27.6 (1.38-92.7) months for those with 
elevated insulin exposure and 26.6 (0.92-96.2) for those without diabetes 
(p=0.8623). Adjusting for potential confounders, there was no significant effect of 
insulin exposure on the time to tumor progression, although it appeared that 
elevated insulin exposure may increase the risk of progression, while physiologic 
exposure decreases the risk of progression compared to non-diabetics (Table 3). 
Only the use of steroids prior to recurrence was found to have a statistically 
significant impact on the time to tumor progression. A 68% decrease (p=0.019) in 
the risk of progression over the five years studied was found in patients that used 
corticosteroids when controlling for other factors. 
 
Similar to the primary endpoint analysis, the covariates containing incomplete 
data were eliminated from the model to improve the evaluable population. In 
eliminating the effects of Charlson score and stage, the use of bisphosphonates 
was found to increase the risk of recurrence by 1.21-4.59 times compared with 
those that did not have bisphosphonate exposure (p=0.001-0.012) (Appendix 
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Tables 5-6). Adjusting for comorbidities and stage through evaluating 
hypercholesterolemia, hypertension, and the presence of metastases at 
diagnosis revealed similar effects. Bisphosphonate use appeared to significantly 
increase the risk of progression, despite controlling for comorbidities. Within this 
analysis, bisphosphonates were used across all stages of disease. Further 
investigation of interaction between Charlson score and bisphosphonate use 
demonstrated no interaction. (Appendix Table 7) 
 
Finally, the duration of diabetes prior to prostate cancer development appeared 
to increase the risk of progression by 30% for every year diagnosed (95% CI: 
1.09-1.73; p=0.007), although this analysis was only available in a small 
population (Appendix Table 8).  
 
In evaluating the effect of the presence of DM, regardless of medication use, on 
cancer development and progression, diabetics appeared to have no difference 
in the grade of tumor at diagnosis, but may have reduced risk of progressive 
disease when HTN and hypercholesterolemia are controlled for. The complete 
analysis of the effects of DM regardless of medication treatment can be found in 
Appendix Tables 9-16. 
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Figure 1: Patient selection for cases and randomly selected controls 
  
Patients with outpatient prescription 
medication information 
(n=863) 
Male patients with diagnosis of 
prostate cancer in the KM database 
(n=1272) 
Age > 18 
(n=1269) 
Diagnosis of DM prior to recurrence 
(n=853) 
Both diagnosis of DM and use of  
prescription therapy 
(n=761) 
Antidiabetic MPR >80% 
(n=722) 
Elevated 
insulin 
exposure 
(n=103) 
Indeterminate 
insulin 
exposure* 
(n=16) 
Randomly age-
matched 
controls 
(n=338) 
Physiologic 
insulin 
exposure 
(n=50) 
* Patients with indeterminate exposure were excluded from the final analysis 
 
 
Table 1: Patient Demographic Information 
 
 
Elevated 
insulin 
exposure 
Physiologic 
insulin 
exposure 
No evidence 
of DM Total p-value 
N 103 (20.98%) 50 (10.18%) 338 (68.84%) 491  
Age, years (mean,SD) 70.8 (±9.78) 71.2 (±9.32) 70.6 (±10.18) 70.7 (±9.99) 0.9250 
Geography 0.651 
Urban 32 (31.07%) 10 (20.00%) 96 (28.40%) 138 (28.11%)  
Suburban 16 (15.53%) 11 (22.00%) 61 (18.05%) 88 (17.92%)  
Rural 55 (53.40%) 29 (58.00%) 181 (53.55%) 265 (53.97%)  
Stage* n=62 n=30 n=202 n=294 0.281 
Localized 46 (74.19%) 26 (86.67%) 142 (70.30%) 214 (72.79%)  
Regional 4 (6.45%) 0 (0%) 11 (5.45%) 15 (5.10%)  
Distant Metastases 7 (11.29%) 2 (6.67%) 39 (19.31%) 48(16.33%)  
Unknown/unstageable 5 (8.06%) 2 (6.67%) 10 (4.95%) 17 (5.78%)  
Presence of metastases at diagnosis 0.159 
No 96 (93.20%) 48 (96.00%) 299 (88.46%) 443 (90.22%)  
Yes 7 (6.80%) 2 (4.00%) 39 (11.54%) 48 (9.78%)  
Metastatic sites 0.119 
No metastatic sites 96 (93.20%) 48 (96.00%) 299 (88.46%) 443 (90.22%)  
Bone/Spine 1 (0.97%) 2 (4.00%) 15 (4.44%) 18 (3.67%)  
Other sites 6 (5.83%) 0 (0%) 24 (7.10%) 30 (6.11%)  
Comorbidity Information 
Charlson scores (median, 
range)* 
2 (1-7) 
n=86 
2 (1-5) 
n=40 
1 (1-12) 
n=173 
2 (1-12) 
n=299 0.0351 
Presence of Hypertension      <0.001 
No 5 (4.85%) 1 (2.00%) 62 (18.34%) 68 (13.85%)  
Yes 98 (95.15%) 49 (98.00%) 276 (81.66%) 423 (86.15%)  
Table 1: P
atient D
em
ographic Inform
ation continued on page 20 
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Presence of 
Hypercholesterolemia     <0.001 
No 51 (49.51%) 23 (46.00%) 233 (68.93%) 307 (62.53%)  
Yes 52 (50.49%) 27 (54.00%) 105 (31.07%) 184 (37.47%)  
Medication Use 
Chemotherapy Use     0.088 
No 90 (87.38%) 49 (98.00%) 308 (91.12%) 447 (91.04%)  
Yes 13 (12.62%) 1 (2.00%) 30 (8.88%) 44 (8.96%)  
Antiandrogen/GNRH 
agonist use     0.869 
No 82 (79.61%) 38 (76.00%) 266 (78.70%) 386 (78.62%)  
Yes 21 (20.39%) 12 (24.00%) 72 (21.30%) 105 (21.38%)  
Bisphosphonate Use     0.706 
No 96 (93.20%) 48 (96.00%) 311 (92.01%) 455 (92.67%)  
Yes 7 (6.80%) 2 (4.00%) 27 (7.99%) 36 (7.33%)  
Corticosteroid Useǂ     0.118 
No 82 (79.61%) 45 (90.00%) 262 (77.51%) 389 (79.23%)  
Before diagnosis 5 (4.85%) 1 (2.00%) 8 (2.37%) 14 (2.85%) 0.346 
Spanning diagnosis 12 (11.65%) 4 (8.00%) 43 (12.72%) 59 (12.02%) 0.722 
After diagnosis 4 (3.88%) 0 (0.00%) 25 (7.40%) 29 (5.91%) 0.068 
Diabetes Information 
Time diagnosed with DM, 
years (median, range) 4.2 (0.16-9.61) 3.9 (0.16-9.59) 0 (0) 4.1 (0.16-9.61) 0.5147 
Time from diagnosis of 
DM to diagnosis of PCa, 
years (mean, SD) 
1.8 (±1.89) 1.8 (±2.01) 0 (0) 1.8 (±1.93) 0.8507  
Table 1: P
atient D
em
ographic Inform
ation continued on page 21 
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Antidiabetic Medication Use 
Sulfonylurea use       
No sulfonylurea use 10 (9.71%) 38 (76.00%) 338 (100%) 386 (78.62%)  
Sulfonlyurea + other DM 69 (66.99%) 12 (24.00%) 0 (0%) 81 (16.50%) <0.001 
Exclusive sulfonylurea 24 (23.30%) 0 (0%) 0 (0%) 24 (4.89%) <0.001 
Thiazolendione use (TZD)      
No TZD use 69 (66.99%) 26 (52.00%) 338 (100%) 433 (88.19%)  
TZD + other DM med 34 (33.01%) 18 (36.00%) 0 (0%) 52 (10.59%) <0.001 
Exclusive TZD 0 (0%) 6 (12.00%) 0 (0%) 6(1.22%) <0.001 
Metformin use      
No metformin use 48 (46.60%) 19 (38.00%) 338 (100%) 405 (82.48%)  
Metformin + other DM 55 (53.40%) 17 (34.00%) 0 (0%) 72 (14.66%) <0.001 
Exclusive metformin 0 (0%) 14 (28.00%) 0 (0%) 14 (2.85%) <0.001 
Insulin use      
No insulin use 60 (58.25%) 31 (62.00%) 338 (100%) 429 (87.37%)  
Insulin+ other DM 37 (35.92%) 14 (28.00%) 0 (0%) 51 (11.88%) <0.001 
Exclusive insulin 6 (5.83%) 5 (10.00%) 0 (0%) 11 (2.24%) <0.001 
Average Medication 
Possession Ratio (MPR) 
of Diabetic Meds (median, 
range) 
1.00 (0.80-
4.72) 
0.99 (0.82-
3.53) 0 (0) 
1.00 (0.80-
4.72) 0.7974 
Use of antidiabetic 
medications after PCa dx 
(as percent of total 
DMgrp) 
14 (13.59%) 11 (22.00%) 0 (0%) 25 (5.09%)  
*Not available for all patients; number evaluated listed 
ǂDifferences between the steroid group overall listed first; differences listed with each point of steroid use (before, during, after) are listed 
at the point of use – these were determined from dichotomous values (e.g. used/did not use steroid before diagnosis) 
21 
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Figure 2: Gleason score based on insulin exposure 
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Table 2: Multivariate Analysis of Odds of Developing High Gleason Score Based 
on Insulin Exposure (n=133) 
 Odds 
Ratio 
95% Confidence 
Interval p-value 
Rurality    
Urban Reference   
Suburban 0.50 (0.17-1.52) 0.222 
Rural 0.74 (0.30-1.80) 0.500 
Charlson score 1.07 (0.79-1.44) 0.670 
Corticosteroid Use (before dx)    
No Reference   
Yes 1.47 (0.23-9.46) 0.685 
Diabetes Group    
No Diabetes Reference   
Elevated insulin exposure 1.04 (0.44-2.44) 0.929 
Physiologic insulin exposure 0.61 (0.22-1.70) 0.350 
Physiologic compared to 
elevated 0.61 (0.23-1.62) 0.320 
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Figure 3: Kaplan Meier Analysis of Time to Progression by Insulin Exposure  
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Table 3: Multivariate Analysis of Hazard of Prostate Cancer Progression (n=168) 
 Hazard 
Ratio 
95% 
Confidence 
Interval 
p-value 
Rurality    
Urban Reference   
Suburban 0.82 (0.31-2.15) 0.684 
Rural 0.68 (0.30-1.53) 0.351 
Charlson score 0.85 (0.62-1.16) 0.313 
Stage    
Localized Reference   
Regional 0.96 (0.28-3.30) 0.945 
Distant Metastases 0.96 (0.36-2.53) 0.926 
Unknown/unstageable 1.83 (0.42-8.01) 0.421 
Corticosteroid Use  
(prior to recurrence)    
No Reference   
Yes 0.32 (0.13-0.83) 0.019 
Bisphosphonate Use 
(prior to recurrence)    
No Reference   
Yes 2.01 (0.64-6.35) 0.232 
Antiandrogen/GNRH 
agonist use 
(prior to recurrence)    
No Reference   
Yes 0.91 (0.43-1.93) 0.814 
Diabetes Group    
No Diabetes Reference   
Elevated insulin 
exposure 1.18 (0.57-2.44) 0.649 
Physiologic insulin 
exposure 0.62 (0.22-1.73) 0.363 
Physiologic compared to 
elevated 0.58 (0.22-1.53) 0.272 
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SECTION FOUR: DISCUSSION 
This study found that management of diabetes with medications which create 
supra-physiologic insulin exposure does not lead to more aggressive prostate 
cancers at diagnosis and shorter time to progression. Previous analyses have 
demonstrated a link between diabetes and developing cancer, an effect which is 
potentially modified by the choice of antidiabetic treatment.33-37 In vitro studies 
clearly demonstrate that insulin can stimulate IGFR-1 receptors in prostate 
cancer cell lines and stimulate mitogenic and angiogenesis pathways.  These 
findings suggest that this isn’t a disease-disease interaction, but rather a disease 
treatment – disease interaction.  While several others have evaluated the 
association of diabetes and cancer, none have evaluated disease management 
leading to increased insulin exposure with prostate cancer biology and 
progression.     
 
The findings in this analysis are consistent with the work reported by Weinstein et 
al. who evaluated the in vitro application of human insulin and human insulin 
analogs to prostate tumor cells.28 Here, recombinant human insulin was found to 
slightly increase growth, but not significantly when compared to control cells. 
When forming the hypothesis, this data was considered, but the in-vivo data 
presented by Venkateswaran was more compelling.  In this, mice with high 
serum insulin were found to have increased tumor growth over those with low 
circulating insulin.30  This data supports the hypothesis that insulin increases cell 
growth. Based on the major principle of cancer biology, that increased growth 
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increases cellular instability and increases tumor grade, it is reasonable to then 
think that insulin may increase the mitogenic growth of prostate tumors and 
increase tumor grade as further stated in the hypothesis explored.53 
  
However, recent data released by the Health Professionals Study suggest that 
low-grade tumors (Gleason score <7) are associated with higher levels of insulin-
like growth factor and binding protein (IGF-1 and IGFBP-3), a finding that is 
counter to the proposed mechanism seen in this study and previous literature 
evaluations.54 The data in the Health Professionals Study suggests that 
increasing insulin levels may actually lead to lower-grade tumors in patients with 
high serum insulin who develop cancer. From this, alternate hypothesis for 
increased high-grade tumors in patients with elevated insulin exposure should be 
further investigated, including the effect of DM on testosterone. Diabetes is linked 
with lower levels of circulating testosterone, a known stimulatory agent of 
prostate cancer growth. Further, testosterone has been associated with higher 
grade tumors, a finding that supports what was seen in the studies by Hong and 
DeNuzio.55-57 As demonstrated there are conflicting reports, and potentially 
conflicting underlying biochemical mechanisms regarding the effect of diabetes 
on prostate tumor grade. This highlights the importance of further study in this 
area with clear measurement of the effect of serum insulin, insulin/IGFR-1 
receptors and testosterone on tumor grade. 
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Looking at the effects between cancer and insulin in diabetic patients in 
epidemiologic data, the presence of diabetes has been shown to increase the 
risk of high grade prostate tumor development, a finding that is not supported by 
this analysis. Hong et al. found that in patients undergoing prostate biopsy, those 
with self-reported DM were found to have a 1.54 times higher odds of developing 
tumors with Gleason score ≥7.15 Similarly, De Nunzio et al. recently published a 
similar study that found that patients with metabolic syndrome (defined by the 
ATPIII criteria – the measured presence of 3 of the following: abdominal obesity, 
hypertriglyceridemia, low high-density lipoprotein cholesterol, hypertension or 
high fasting blood glucose) had a 3.82 times higher risk of high-grade tumors 
(Gleason ≥7).40 While both of these analyses demonstrate increased grade 
tumors in diabetic patients, the methods of defining diabetes are subject to bias 
or are limited by one-time evaluation, potentially altering the results.  
 
Other studies on the effect of DM on tumor grade report findings more similar to 
what is seen here – diabetes potentially decreases the odds of high grade 
prostate tumor development. Gong et al. reported a decreased in the odds of 
higher-grade tumors in patients with self-reported DM (OR=0.72 (0.55-0.94)), 
although again the definition of DM in these patients is subject to recall bias. 
Additionally in Gong’s analysis, patients with higher BMI and weight also were 
found to have an increased odds of high-grade tumor development.6 Previous 
studies evaluating the effect of metabolic syndrome have found similar results, 
independent of the effects of DM and insulin exposure, most likely through 
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alterations in lipid and androgen metabolism.58 Farwell et al. recently reported a 
10% increase in the risk of high-grade tumors in patients with elevated baseline 
total cholesterol, while Llaverias et al. found that mice fed high-fat/high-
cholesterol diets had increased cellular proliferation and metastatic spread.59,60 
Although the models within this study were unable to account for BMI and weight, 
hypercholesterolemia was not found to have an effect on tumor grade or 
progression, contrary to previous analysis. These findings suggest that the 
interaction between DM, other factors in metabolic syndrome, serum insulin and 
tumor growth is complex.  
Although epidemiologic evidence exists suggesting that the use of antidiabetic 
therapy may alter the development of prostate tumors, again, no evidence exists 
that these agents alter tumor grade. In this evaluation, the use of insulin 
stimulating agents was associated with a slight increase in high grade tumors 
while non-stimulating agents were associated with a lower grade tumor 
compared to those without diabetes. While this is not statistically significant, this 
does provide evidence that perhaps the increase in serum insulin seen may lead 
to increased mitogenic effects. This study was only able to access data from the 
Kentucky Medicaid database over a 5 year period. Evaluation in a larger 
database, such as the Veteran’s Administration databases may provide further 
clarity on the effect of diabetic medication use on the development of high-grade 
prostate tumors.  
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Similarly, the difference in the time to tumor progression based on the use of 
antidiabetic medications has not been previously evaluated in the literature. 
Overall, this study found a potentially lower risk of tumor progression in those 
using TZDs, metformin or low-dose insulin compared to non-diabetics and a 
higher risk of progression in those using sulfonylureas or high-dose insulin 
compared to non-diabetics. Although this was not statistically significant, this 
observed phenomena may be due in part to independent anti-tumor affects of 
metformin and TZDs outside of their effects on serum insulin. Metformin has 
been shown inhibit in-vitro growth of prostate cell lines through AMPK activation 
and mTOR inhibiton.61 Thiazolidinediones have also been shown to have 
independent anti-tumor activity in vitro. This effect is thought to be primarily 
through the activation of PPAR-γ, although PPAR-γ independent mechanisms 
have also been suggested.62 Although sulfonylureas have not yet been shown to 
have antitumor effects, it is thought that the effects on increased tumor risk and 
mortality seen with sulfonylureas may be a statistical abnormality due to the 
comparison to those with known anti-tumor activity.63 In this study metformin and 
TZDs were associated with a potentially decreased time to progression, while 
sulfonylureas had a slight increase in progression. Since the anti-tumor effects 
were unable to be accounted for it is difficult to ascertain if the effects seen were 
a result of the effect on insulin, or a modification of alternate tumorgenic cellular 
pathways by diabetic medications.  
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Alternate models found an overall decrease in tumor progression in patients with 
elevated and physiologic insulin exposure compared to those without DM. Similar 
to the results of the primary evaluation, this was not statistically significant, but 
leads to interesting observations on the effect of DM on tumor progression. In 
addition to potential anti-tumor effects of diabetic medications, the decrease in 
progression risk in those with elevated exposure may indicated a protective effect 
of physiologic changes in diabetic patients. Vascular changes are common in 
diabetics, often leading to numerous complications on end-organs. Post-hoc 
analysis demonstrated that overall case patients in both groups had a lower 
incidence of metastatic disease than non-diabetics, indicating that despite 
potentially higher grade at diagnosis, diabetics may have less metastatic spread 
due to poor vascularization. This hypothesis could not be evaluated in this 
analysis, but should continue to be investigated in future studies.  
 
In addition to the effects of antidiabetic agents, several covariates were found to 
alter the time to tumor progression. Patients with longer durations of DM prior to 
tumor diagnosis were found to have an increased risk of progression, adjusted 
for use of different diabetic medications. Previous studies have shown a 
decreased risk of tumor development in those with longer duration of DM, 
although the effect of this on progression in unknown.13,14 Future study in this 
area should adjust for actual serum levels since it appears that there is a 
disparate effect seen in patients with changing insulin exposures.  
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Corticosteroid use was consistently found to reduce the risk of progressive 
disease, a finding that is not well evaluated in the literature. While corticosteroids 
today are primarily used to reduce the inflammation and pain of metastatic 
lesions, early studies suggested that they may play a role in inhibiting adrenal-
produced testosterones. 64  Short term corticosteroid use may have no effect on 
testosterone levels, but long term use in older patients has been shown to have a 
dose-dependent decrease in serum testosterone.65,66 Within this analysis, 
steroids were used across all metastatic sites, including some use in those 
without known metastatic disease. The potential decrease in serum testosterone 
may have led to delayed progression within these patients, although will need to 
be further studied. 
 
Although bisphosphonates are typically shown to limit tumor progression, this 
analysis found that patients using these agents had a significantly increased risk 
of progression.  Bisphosphonates have been shown in numerous cellular studies 
to inhibit cell signaling pathways that are critical to tumor proliferation, invasion 
and adhesion.38,67,68 Conversely, in-vivo mouse models have shown that the use 
of prophylactic and treatment zoledronic acid were not associated with 
decreased tumor growth or metastatic spread.69 Although human studies have 
demonstrated the effect of bisphosphonates to improve quality of life and reduce 
skeletal-related events in prostate cancer patients, the use of these agents is 
typically limited to those with metastatic or highly aggressive disease. The 
increase risk of progression due to bisphosphonate use may be an artifact of the 
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correlation of bisphosphonate use to metastatic patients with high tumor burden 
in bone, a characteristic which could not be discerned in this dataset. Since this 
effect was not seen until stage was no longer evaluated as a covariate, it is 
possible that the risk seen is merely a measure of the risk of progression in 
higher stage disease.  
 
All studies have strength and limitations. This study had several factors that may 
have limited the ability to detect a difference in tumor grade and progression 
between users of different antidiabetic medications. First, the sample size was 
small for the type of large-cohort analysis conducted. Although the trends seen in 
regards to the effects of insulin exposure on tumor grade support the hypothesis, 
the lack of power in this analysis leads to inconclusive results. Additionally, 
changes in endogenous secretion of insulin in patients on anti-diabetic 
medications could not be accounted for. This lack of quantitation of insulin may 
have led to unknown misclassification within the exposure groups, potentially 
skewing the results. Although the duration of DM was accounted for, it was 
limited to what was observed during the study period – thus any long-term effects 
of diabetes treatment prior to study initiation is unaccounted for. Further, as 
discussed above, this study was unable to adjust for potential independent 
chemotherapeutic effects of anti-diabetic treatments. Finally, analysis using large 
billing databases is always subject to misclassification, although this was limited 
through a thorough review of the available data. 
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SECTION FIVE: CONCLUSION 
The use of antidiabetic medications that cause high insulin exposure did not 
increase the grade of prostate tumor upon diagnosis or decrease the time to 
tumor progression in this analysis. Although the results were are inconclusive this 
data provides needed insight into the interactions between diabetes treatments 
and the development and progression of prostate tumors. While this study was 
underpowered to provide any conclusive results, the hypothesis remains credible 
and should continue to be investigated through larger database analyses, as well 
as potential prospective studies. As seen, there is a multitude of factors that 
interplay within the proposed mechanism to lead to tumor development and 
progression. Future analysis should consider an evaluation of serum insulin, 
weight, BMI,  lipids (cholesterol, HDL, LDL, TG), testosterone, and IGFR-1 
expression on pathologic samples, along with robust medical histories (including 
complete antidiabetic and lipid-lowering agents, bisphosphonate use, hormone 
therapy, and steroid medications histories) in order to fully evaluate the effect of 
medications on prostate tumors. Through a better characterization of these 
interactions, future treatment of patients with diabetes and prostate cancer may 
be optimized and overall health outcomes improved. 
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Appendix Table 1: NDC Codes used to determine medication classifications 
 
Drug  Insulin 
Exposure 
Group 
Medication 
Class 
NDC 
Acarbose Excluded Antidiabetic 26286148, 26286151, 
26286251, 26286351, 
16250000000 
Chlorpropamide 
 
Elevated 
Insulin 
Exposure 
Antidiabetic 50110000000 
Exenatide Excluded Antidiabetic 66780000000 
 
Glimepiride 
 
Elevated 
Insulin 
Exposure 
Antidiabetic 39022110, 39022210, 
39022211, 39022310, 
39022311, 55110000000, 
63300000000, 
66990000000 
Glipizide Elevated 
Insulin 
Exposure 
Antidiabetic 49155066, 49155073, 
49156066, 49156073, 
49162030, 172400000, 
378100000, 591000000, 
591100000, 781100000, 
51080000000, 
51290000000, 
52540000000, 
59760000000, 
60510000000, 
62040000000 
Glyburide Elevated 
Insulin 
Exposure 
Antidiabetic 9017105, 9035204, 
9344903, 39005210, 
93803501, 93834301, 
93834305, 93834310, 
93834401, 93834405, 
93834410, 93936401, 
93936405, 93936410, 
93943301, 93943305, 
93947753, 378100000, 
781100000, 38250000000, 
38250000000, 
51080000000, 
55370000000, 
55950000000, 
59760000000, 
59760000000, 
67250000000 
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Glyburide/metformin Elevated 
Insulin 
Exposure 
Antidiabetic 87607211, 87607311, 
87607411, 93571201, 
93571205, 172600000, 
228300000, 781500000, 
49880000000 
Insulin Elevated 
Insulin 
Exposure if 
avgqty >20mL 
Q30days 
(determined 
on avg supply 
since such 
variation in 
day supply. 
This is based 
on 
0.8units*85kg
=68units/day; 
100 units/mL= 
~20mL/month) 
 
 
Physiologic 
Insulin 
Exposure if 
avgqty <20mL 
Q30days 
Antidiabetic 2751001, 2751101, 
2821501, 2831001, 
2831501, 2861501, 
2871501, 2872559, 
2873059, 2877059, 
2879459, 69005053, 
88222033, 88222060, 
169000000, 169200000, 
169200000, 169200000, 
169200000, 169200000, 
169200000, 169300000, 
169300000, 169400000, 
169600000, 169800000, 
59060000000 
Metformin Physiologic 
Insulin 
Exposure 
Antidiabetic 87606005, 87606010, 
87606313, 87607005, 
87607010, 87607111, 
87607112, 93104801, 
93104805, 93104810, 
93104901, 93104905, 
93721401, 93721405, 
93726701, 93726710, 
172400000, 172400000, 
185000000, 185400000, 
228300000, 378000000, 
555000000, 591200000, 
591300000, 781500000, 
904600000, 49880000000, 
49880000000, 
51080000000, 
53490000000, 
57660000000, 
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60510000000, 
60510000000, 
62020000000, 
62040000000, 
62040000000, 
62580000000, 
62760000000, 
63300000000, 
65860000000, 
68380000000 
Miglitol Excluded Antidiabetic 9501201, 9501301, 
9501401 
Nateglinide Excluded Antidiabetic 78035105, 78035205 
Pioglitazone Physiologic 
Insulin 
Exposure 
Antidiabetic 64760000000 
Pioglitazone/ 
metformin 
Physiologic 
Insulin 
Exposure 
Antidiabetic 64760000000 
Repaglinide Excluded Antidiabetic 169000000 
Rosiglitazone Physiologic 
Insulin 
Exposure 
Antidiabetic 29315818, 29315913, 
29315918, 29315920, 
29316013, 29316020 
Rosiglitazone/ 
metformin 
 
Physiologic 
Insulin 
Exposure 
Antidiabetic 7316418, 7316718, 
7316720, 7316818, 
7316820 
Sitagliptin Excluded Antidiabetic 6027731 
Troglitazone Physiologic 
Insulin 
Exposure 
Antidiabetic 71035223, 71035315, 
71035323, 71035720 
Bicalutamide  Antiandrogen/ 
GNRH agonist 
93022056, 310100000 
Flutamide  Antiandrogen/ 
GNRH agonist 
85052506, 93712086, 
172500000, 555100000 
Ketoconazole  Antiandrogen/ 
GNRH agonist 
93090001, 51670000000 
Nilutamide  Antiandrogen/ 
GNRH agonist 
88111035, 88111114 
Goserelin  Antiandrogen/ 
GNRH agonist 
310100000 
 
Leuprolide  Antiandrogen/ 
GNRH agonist 
300200000, 300300000, 
300400000 
Alendronate  Bisphosphonate 6003121, 6003144, 
6007744, 6092531, 
6093628, 6093631, 
6093658, 93517120, 
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93517144 
Ibandronate  Bisphosphonate 4018682 
Pamidronate  Bisphosphonate 83260901, 55390000000 
Risedronate  Bisphosphonate 149000000 
Zoledronic acid  Bisphosphonate 78035084, 78038725 
Dexamethasone  Steroids 54317763, 54418025, 
54418125, 54418325, 
54418425, 54817525, 
95008651, 402100000, 
517500000, 603300000, 
641000000, 703400000, 
904000000, 49880000000, 
60430000000, 
63320000000 
Fludrocortisone  Steroids 3042950, 115700000, 
555100000 
Hydrocortisone  Steroids 6061968, 9001201, 
9003101, 9082501, 
143100000, 536400000, 
574200000, 677000000, 
39820000000 
Methylprednisolone  Steroids 9019009, 9019016, 
9030602, 9307301, 
9307303, 9347501, 
74568502, 182100000, 
254400000, 527100000, 
536400000, 555000000, 
591100000, 603500000, 
677100000, 781500000, 
49880000000, 
51290000000, 
52540000000, 
59750000000, 
59760000000, 
62270000000, 
63300000000 
Prednisolone  Steroids 58180000000, 
59200000000, 
60430000000, 
65580000000 
Prednisone  Steroids 9004501, 9004502, 
9004516, 9016501, 
9016502, 9019301, 
9019302, 9038801, 
54001720, 54001725, 
54001729, 54001820, 
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54001825, 54001829, 
54472825, 54472831, 
54472925, 54472929, 
54473025, 54473029, 
54473325, 54474125, 
54872425, 54872525, 
54872625, 54874025, 
143100000, 182100000, 
254500000, 259000000, 
364000000, 536400000, 
591500000, 603500000, 
677000000, 677100000, 
904200000, 51080000000, 
52540000000,  
53490000000 
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Appendix Table 2: Multivariate Analysis of Odds of Developing High Gleason 
Score Based on Insulin Exposure (n=236; eliminating Charlson score as a 
covariate) 
 
 Odds 
Ratio 
95% Confidence 
Interval p-value 
Rurality    
Urban Reference   
Suburban 0.68 (0.31-1.50) 0.338 
Rural 0.93 (0.49-1.73) 0.808 
Corticosteroid Use (before dx)    
No Reference   
Yes 1.27 (0.21-7.75) 0.798 
Diabetes Group    
No Diabetes Reference   
Elevated insulin exposure 0.98 (0.48-1.97) 0.946 
Physiologic insulin exposure 0.56 (0.21-1.49) 0.245 
Physiologic compared to 
elevated 0.56 (0.22-1.48) 0.244 
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Appendix Table 3: Multivariate Analysis of Odds of Developing High Gleason 
Score Based on Insulin Exposure (n=236; uses presence of hypertension and 
hypercholesterolemia as a measure of comorbid disease) 
 
 Odds 
Ratio 
95% Confidence 
Interval p-value 
Rurality    
Urban Reference   
Suburban 0.67 (0.30-1.48) 0.318 
Rural 0.90 (0.46-1.73) 0.741 
Presence of HTN    
No  Reference   
Yes 0.67 (0.31-1.45) 0.306 
Presence of Hypercholesterolemia    
No Reference   
Yes 1.12 (0.61-2.04) 0.715 
Corticosteroid Use (before dx)    
No Reference   
Yes 1.17 (0.19-7.26) 0.867 
Diabetes Group    
No Diabetes Reference   
Elevated insulin exposure 1.00 (0.49-2.08) 0.988 
Physiologic insulin exposure 0.59 (0.22-1.60) 0.304 
Physiologic compared to elevated 0.59 (0.22-1.57) 0.293 
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Appendix Table 4: Multivariate Analysis of Odds of Developing High Gleason 
Score Based on Insulin Exposure (n=61; includes measure of duration of DM 
diagnosis prior to prostate cancer) 
 
 Odds 
Ratio 
95% Confidence 
Interval p-value 
Rurality    
Urban Reference   
Suburban 0.76 (0.13-4.48) 0.762 
Rural 0.34 (0.05-2.29) 0.267 
Presence of HTN    
No  Reference   
Yes Dropped – all those without HTN (#2) did 
not have a high Gleason  
Presence of Hypercholesterolemia    
No Reference   
Yes 2.54 (0.43-14.94) 0.302 
Corticosteroid Use (before dx)    
No Reference   
Yes 2.04 (0.10-41.4) 0.641 
Diabetes Group    
No Diabetes Reference   
Elevated insulin exposure N/A N/A N/A 
Physiologic insulin exposure 0.49 (0.15-1.65) 0.250 
Physiologic compared to elevated N/A N/A N/A 
Duration of DM diagnosis prior to 
PCa(yr) 0.87 (0.58-1.33) 0.528 
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Appendix Table 5: Multivariate Analysis of Hazard of Prostate Cancer 
Progression (n=294; eliminating Charlson score as a covariate) 
 
 Hazard 
Ratio 
95% 
Confidence 
Interval 
p-value 
Rurality    
Urban Reference   
Suburban 0.79 (0.40-1.55) 0.496 
Rural 0.80 (0.47-1.36) 0.416 
Stage    
Localized Reference   
Regional 0.94 (0.36-2.41) 0.890 
Distant Metastases 0.95 (0.47-1.90) 0.881 
Unknown/unstageable 0.77 (0.28-2.15) 0.623 
Corticosteroid Use  
(prior to recurrence)    
No Reference   
Yes 0.53 (0.27-1.03) 0.060 
Bisphosphonate Use 
(prior to recurrence)    
No Reference   
Yes 2.36 (1.21-4.59) 0.012 
Antiandrogen/GNRH agonist  
(prior to recurrence)    
No Reference   
Yes 1.02 (0.61-1.70) 0.950 
Diabetes Group    
No Diabetes Reference   
Elevated insulin exposure 0.95 (0.54-1.68) 0.872 
Physiologic insulin exposure 0.59 (0.23-1.51) 0.272 
Physiologic compared to 
elevated 0.60 (0.24-1.51) 0.278 
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Appendix Table 6: Multivariate Analysis of Hazard of Prostate Cancer 
Progression (n=491; eliminating Charlson score and stage as a covariate) 
 
 Hazard 
Ratio 
95% 
Confidence 
Interval 
p-value 
Rurality    
Urban Reference   
Suburban 1.14 (0.68-1.91) 0.622 
Rural 0.85 (0.56-1.30) 0.464 
Corticosteroid Use  
(prior to recurrence)    
No Reference   
Yes 0.56 (0.34-0.93) 0.025 
Bisphosphonate Use 
(prior to recurrence)    
No Reference   
Yes 2.44 (1.46-4.06) 0.001 
Antiandrogen/GNRH agonist use  
(prior to recurrence)    
No Reference   
Yes 1.20 (0.79-1.83) 0.390 
Diabetes Group    
No Diabetes Reference   
Elevated insulin exposure 0.75 (0.46-1.20) 0.231 
Physiologic insulin exposure 0.53 (0.26-1.10) 0.086 
Physiologic compared to 
elevated 0.56 (0.27-1.16) 0.117 
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Appendix Table 7: Multivariate Analysis of Hazard of Prostate Cancer 
Progression (n=491; uses presence of hypertension and hypercholesterolemia as 
a measure of comorbid disease) 
Variable Hazard 
Ratio 
95% 
Confidence 
Interval 
p-value 
Rurality    
Urban Reference   
Suburban 1.10 (0.65-1.85) 0.728 
Rural 0.79 (0.51-1.23) 0.300 
Presence of HTN    
No  Reference   
Yes 0.87 (0.52-1.48) 0.618 
Presence of 
Hypercholesterolemia    
No Reference   
Yes 1.35 (0.92-1.98) 0.127 
Presence of metastases at 
diagnosis    
No Reference   
Yes 0.93 (0.48-1.81) 0.840 
Corticosteroid Use  
(prior to recurrence)    
No Reference   
Yes 0.58 (0.35-0.97) 0.037 
Bisphosphonate Use 
(prior to recurrence)    
No Reference   
Yes 2.41 (1.44-4.04) 0.001 
Antiandrogen/GNRH agonist  
(prior to recurrence)    
No Reference   
Yes 1.25 (0.81-1.91) 0.311 
Diabetes Group    
No Diabetes Reference   
Elevated insulin exposure 0.73 (0.45-1.18) 0.198 
Physiologic insulin 
exposure 0.50 (0.24-1.06) 0.070 
Physiologic compared to 
elevated 0.55 (0.26-1.14) 0.106 
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Appendix Table 8: Multivariate Analysis of Hazard of Prostate Cancer 
Progression (n=153; includes measure of duration of DM diagnosis prior to 
prostate cancer) 
 
Variable Hazard 
Ratio 
95% 
Confidence 
Interval 
p-value 
Rurality    
Urban Reference   
Suburban 2.19 (0.79-6.08) 0.133 
Rural 0.57 (0.20-1.66) 0.303 
Presence of HTN    
No  Reference   
Yes 1.17 (0.14-9.63) 0.880 
Presence of Hypercholesterolemia    
No Reference   
Yes 1.37 (0.59-3.20) 0.466 
Presence of metastases at 
diagnosis    
No Reference   
Yes 1.07 (0.13-8.58) 0.947 
Corticosteroid Use  
(prior to recurrence)    
No Reference   
Yes 0.31 (0.08-1.12) 0.073 
Bisphosphonate Use 
(prior to recurrence)    
No Reference   
Yes 4.16 (1.28-13.5) 0.017 
Antiandrogen/GNRH agonist use  
(prior to recurrence)    
No Reference   
Yes 1.04 (0.43-2.53) 0.925 
Diabetes Group    
No Diabetes Reference   
Elevated insulin exposure N/A N/A N/A 
Physiologic insulin exposure 0.58 (0.24-1.41) 0.230 
Physiologic compared to elevated N/A N/A N/A 
Duration of DM diagnosis prior to 
PCa (years)  1.26 (1.02-1.55) 0.031 
 
  
 
48  
Appendix Table 9: Multivariate Analysis of Odds of Developing High Gleason 
Score Based on Presence of Diabetes (n=133) 
 Odds 
Ratio 
95% Confidence 
Interval p-value 
Rurality    
Urban Reference   
Suburban 0.52 (0.17-1.57) 0.249 
Rural 0.75 (0.31-1.83) 0.532 
Charlson score 1.09 (0.81-1.46) 0.573 
Corticosteroid Use (before dx)    
No Reference   
Yes 1.44 (0.23-9.11) 0.699 
Presence of DM    
No Reference   
Yes 0.84 (0.41-1.75) 0.648 
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Appendix Table 10: Multivariate Analysis of Odds of Developing High Gleason 
Score Based on Presence of Diabetes (n=236; eliminating Charlson score as a 
covariate) 
 
 Odds 
Ratio 
95% Confidence 
Interval p-value 
Rurality    
Urban Reference   
Suburban 0.68 (0.31-1.51) 0.347 
Rural 0.93 (0.50-1.74) 0.819 
Corticosteroid Use (before dx)    
No Reference   
Yes 1.21 (0.20-7.39) 0.835 
Presence of DM    
No Reference   
Yes 0.81 (0.44-1.49) 0.501 
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Appendix Table 11: Multivariate Analysis of Odds of Developing High Gleason 
Score Based on Presence of Diabetes (n=236; uses presence of hypertension 
and hypercholesterolemia as a measure of comorbid disease) 
 
 Odds 
Ratio 
95% Confidence 
Interval p-value 
Rurality    
Urban Reference   
Suburban 0.67 (0.30-1.49) 0.324 
Rural 0.90 (0.46-1.73) 0.742 
Presence of Hypertension    
No Reference    
Yes 0.66 (0.30-1.43) 0.288 
Presence of Hypercholesterolemia    
No Reference   
Yes 1.31 (0.62-2.06) 0.687 
Corticosteroid Use (before dx)    
No Reference   
Yes 1.12 (0.18-6.92) 0.905 
Presence of DM    
No Reference   
Yes 0.84 (0.45-1.59) 0.601 
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Appendix Table 12: Multivariate Analysis of Hazard of Prostate Cancer 
Progression Based on Presence of Diabetes (n=168) 
 Hazard 
Ratio 
95% 
Confidence 
Interval 
p-value 
Rurality    
Urban Reference   
Suburban 0.83 (0.32-2.17) 0.706 
Rural 0.73 (0.33-1.62) 0.439 
Charlson score 0.86 (0.63-1.18) 0.342 
Stage    
Localized Reference   
Regional 1.07 (0.32-3.65) 0.910 
Distant Metastases 0.97 (0.37-2.57) 0.952 
Unknown/unstageable 1.76 (0.40-7.67) 0.452 
Corticosteroid Use  
(prior to recurrence)    
No Reference   
Yes 0.34 (0.13-0.86) 0.024 
Bisphosphonate Use 
(prior to recurrence)    
No Reference   
Yes 2.07 (0.65-6.55) 0.217 
Antiandrogen/GNRH 
agonist use 
(prior to recurrence)    
No Reference   
Yes 0.90 (0.43-1.90) 0.784 
Presence of Diabetes    
No Reference   
Yes 0.96 (0.49-1.87) 0.907 
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Appendix Table 13: Multivariate Analysis of Hazard of Prostate Cancer 
Progression Based on Presence of Diabetes (n=294; eliminating Charlson score 
as a covariate) 
 Hazard 
Ratio 
95% 
Confidence 
Interval 
p-value 
Rurality    
Urban Reference   
Suburban 0.76 (0.39-1.49) 0.427 
Rural 0.81 (0.48-1.37) 0.435 
Stage    
Localized Reference   
Regional 0.98 (0.38-2.51) 0.960 
Distant Metastases 0.95 (0.48-1.91) 0.894 
Unknown/unstageable 0.80 (0.29-2.20) 0.661 
Corticosteroid Use  
(prior to recurrence)    
No Reference   
Yes 0.53 (0.27-1.05) 0.068 
Bisphosphonate Use 
(prior to recurrence)    
No Reference   
Yes 2.38 (1.22-4.64) 0.011 
Antiandrogen/GNRH 
agonist use 
(prior to recurrence)    
No Reference   
Yes 1.01 (0.60-1.69) 0.973 
Presence of Diabetes    
No Reference   
Yes 0.84 (0.50-1.39) 0.493 
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Appendix Table 14: Multivariate Analysis of Hazard of Prostate Cancer 
Progression Based on Presence of Diabetes (n=491; eliminating Charlson score 
and stage as a covariate) 
 Hazard 
Ratio 
95% 
Confidence 
Interval 
p-value 
Rurality    
Urban Reference   
Suburban 1.11 (0.66-1.85) 0.694 
Rural 0.85 (0.56-1.30) 0.451 
Corticosteroid Use  
(prior to recurrence)    
No Reference   
Yes 0.57 (0.34-0.94) 0.028 
Bisphosphonate Use 
(prior to recurrence)    
No Reference   
Yes 2.45 (1.47-4.08) 0.001 
Antiandrogen/GNRH 
agonist use 
(prior to recurrence)    
No Reference   
Yes 1.20 (0.79-1.83) 0.390 
Presence of Diabetes    
No Reference   
Yes 0.67 (0.44-1.02) 0.062 
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Appendix Table 15: Multivariate Analysis of Hazard of Prostate Cancer 
Progression Based on Presence of Diabetes (n=491; uses presence of 
hypertension and hypercholesterolemia as a measure of comorbid disease) 
 
Variable Hazard 
Ratio 
95% 
Confidence 
Interval 
p-value 
Rurality    
Urban Reference   
Suburban 1.07 (0.64-1.79) 0.807 
Rural 0.79 (0.51-1.23) 0.292 
Presence of HTN    
No  Reference   
Yes 0.87 (0.51-1.47) 0.598 
Presence of 
Hypercholesterolemia    
No Reference   
Yes 1.34 (0.91-1.97) 0.135 
Presence of metastases at 
diagnosis    
No Reference   
Yes 0.94 (0.49-1.82) 0.853 
Corticosteroid Use  
(prior to recurrence)    
No Reference   
Yes 0.59 (0.35-0.98) 0.042 
Bisphosphonate Use 
(prior to recurrence)    
No Reference   
Yes 2.43 (1.45-4.07) 0.001 
Antiandrogen/GNRH agonist  
(prior to recurrence)    
No Reference   
Yes 1.25 (0.81-1.91) 0.311 
Presence of Diabetes    
No Reference   
Yes 0.65 (0.42-1.00) 0.051 
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Appendix Table 16: Multivariate Analysis of Hazard of Prostate Cancer 
Progression Based on Presence of Diabetes (n=153; includes measure of 
duration of DM diagnosis prior to prostate cancer) 
 
Variable Hazard 
Ratio 
95% 
Confidence 
Interval 
p-value 
Rurality    
Urban Reference   
Suburban 1.90 (0.70-5.12) 0.206 
Rural 0.59 (0.21-1.67) 0.319 
Presence of HTN    
No  Reference   
Yes 0.93 (0.12-7.30) 0.945 
Presence of 
Hypercholesterolemia    
No Reference   
Yes 1.31 (0.57-3.02) 0.520 
Presence of metastases at 
diagnosis    
No Reference   
Yes 1.11 (0.14-8.87) 0.924 
Corticosteroid Use  
(prior to recurrence)    
No Reference   
Yes 0.34 (0.10-1.22) 0.099 
Bisphosphonate Use 
(prior to recurrence)    
No Reference   
Yes 4.09 (1.27-13.2) 0.018 
Antiandrogen/GNRH agonist  
(prior to recurrence)    
No Reference   
Yes 1.03 (0.42-2.53) 0.942 
Presence of Diabetes    
No Reference   
Yes Dropped due to collinearity with DM 
time variables 
Duration of DM diagnosis 
prior to PCa (years)  1.28 (1.04-1.57) 0.018 
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